Agile Therapeutics
AGRX
AGRX was delisted on the 25th of March, 2024.
64 hedge funds and large institutions have $45.7M invested in Agile Therapeutics in 2021 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 15 increasing their positions, 19 reducing their positions, and 27 closing their positions.
287% more call options, than puts
Call options by funds: $584K | Put options by funds: $151K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
12% less funds holding
Funds holding: 73 → 64 (-9)
21% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 19
33% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 27
42% less capital invested
Capital invested by funds: $79.5M → $45.7M (-$33.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$2.48M |
| 2 |
Morgan Stanley
New York
|
+$1.23M |
| 3 |
Renaissance Technologies
New York
|
+$745K |
| 4 |
TEE
Tibra Equities Europe
London,
United Kingdom
|
+$399K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$382K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$6.25M |
| 2 |
State Street
Boston,
Massachusetts
|
-$1.3M |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$936K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$847K |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$493K |
AGRX Hedge Fund Activity: Q2 2021 in Review
64 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Agile Therapeutics (AGRX) for Q2 2021, worth a combined $45.7M — down 42% from $79.5M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of AGRX and 18 opened new positions — a net loss of 9 holders — while 19 trimmed existing stakes and 15 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $2.48M. The largest seller was BlackRock, cutting an estimated $6.25M.
- 64 institutional investors held Agile Therapeutics (AGRX) as of Q2 2021, down from 73 in Q1 2021.
- Funds reported $45.7M of Agile Therapeutics stock for Q2 2021, down 42% quarter-over-quarter.
- 18 funds opened new Agile Therapeutics positions in Q2 2021 and 27 closed out, a net change of -9 holders.
- The largest Agile Therapeutics buyer in Q2 2021 was Millennium Management, an estimated $2.48M added.
- The largest Agile Therapeutics seller in Q2 2021 was BlackRock, an estimated $6.25M sold.
Based on aggregated 13F filings for Q2 2021.